See ratings and reviews when you sign up for an account.

A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Gentian Violet Oral Solution to That of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings

This study is currently Recruiting

September 2011 By AIDS Clinical Trials Group

First Recieved on November 3, 2010

Last Updated on September 1, 2011

Sponsor: AIDS Clinical Trials Group
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: AIDS Clinical Trials Group
Identifier: NCT01427738


The purpose of this study is to see which one of two medicines (topical gentian violet [GV] or nystatin oral suspension) is better than the other in treating Oral Candidiasis (OC). This will be measured by whether the study participant still has OC or sores in his/her mouth after 14 days of treatment. Also, safety and tolerability of GV and nystatin in the treatment of OC will be assessed.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load. - Pseudomembranous candidiasis documented by a complete oral exam (i.e., white or yellow spots or plaques with an underlying erythematous base that may be located in any part of the oral cavity) at the screening visit. Participants with documented angular chelitis and/or erythematous candidiasis without pseudomembranous candidiasis are not eligible to enroll in the study. - If currently being treated with an ART regimen, initiation of regimen at least 12 weeks prior to study entry, and willingness of participant to remain on current ART regimen until the study-defined 14-day treatment period is complete. NOTE: Participants who are not ART-na?ve and not on ART are eligible to participate in the study if they do not intend to initiate ART during the study- defined 14-day treatment period. - CD4+ cell count obtained within 30 days prior to study entry at a DAIDS-approved laboratory. Exclusion Criteria: - Documented or presumptive signs or symptoms of esophageal candidiasis (e.g., dysphagia) during the screening period unless endoscopic examination of the esophagus was performed and fungal esophagitis was excluded. - Use of any investigational drug currently or within 30 days prior to study entry. NOTE: For purposes of this study, drugs available under an FDA-authorized expanded access program will NOT be considered investigational. - Concurrent vaginal candidiasis within 21 days prior to study entry. - Use of inhaled or systemic corticosteroids within 14 days prior to study entry. - Use of any antifungal agents within 30 days prior to study entry. - Anticipate need for systemic or oral/topical antifungal agents for other diagnoses within the study-defined 14-day treatment period. - Intend to initiate ART during the screening period, at study entry, or within the study-defined 14-day treatment period. - Intend to use any additional oral topical treatments within the study- defined 14-day treatment period. - Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation. - Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. - Serious illness, in the opinion of the site investigator, requiring systemic treatment. - Hospitalization within 30 days prior to study entry for HIV or HIV-related conditions. - Previous or current history of porphyria. - Presence of oral warts during the screening period or at the study entry visit before randomization. - Current wearing of full dentures or a maxillary partial denture at study entry.


  • Investigator: Robert A Salata, MD - Study Chair - Case CRS
  • Investigator: James G Hakim, MD - Principal Investigator - UZ- Parirenyatwa CRS
  • Investigator: Tim Hodgson, MD - Principal Investigator - Eastman Dental Hospital
  • Investigator: Richard J Jurevic, DDS, PhD - Principal Investigator - Case CRS
  • Investigator: Pranab K Mukherjee, PhD, MSc - Principal Investigator - Case CRS
  • Investigator: Cissy M Kityo, MBChB, MSc - Principal Investigator - JCRC CRS
  • Investigator: Rana Traboulsi, MD - Principal Investigator - Case CRS
  • Investigator: Srikanth P Tripathy, MD, MBBS - Principal Investigator - NARI Pune CRS


  • Gaborone Prevention/Treatment Trials CRS (12701)

    Gaborone, Botswana

  • Molepolole Prevention/Treatment Trials CRS (12702)

    Molepolole, Botswana

  • National AIDS Research Institute Pune CRS (11601)

    Pune, Maharashtra 411026 India

  • BJ Medical College CRS (31441)

    Pune, Maharashtra 411001 India

  • AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601)

    Eldoret, 30100 Kenya

  • Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501)

    Kericho, 20200 Kenya

  • College of Med. JHU CRS (30301)

    Blantyre, Malawi

  • Durban Adult HIV CRS (11201)

    Durban, 4013 SF South Africa

  • Joint Clinical Research Centre (JCRC) (12401)

    Kampala, Uganda

  • UZ-Parirenyatwa CRS (30313)

    Harare, Zimbabwe

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.